Can You Restart Your HPG Axis After hCG Monotherapy?

You've been on hCG monotherapy for your secondary hypogonadism. It's working — testosterone is up, testes are intact, fertility preserved. But you want to know: if you stop, can your body take over? Can the axis restart?

The answer is more nuanced than most sources let on. I read everything I could find — clinical trials, mechanistic studies, recovery data, the uncomfortable gaps in the literature. Here's the complete picture.

First: What hCG Is Actually Doing to Your Axis

hCG (human chorionic gonadotropin) mimics LH. It binds the same LH/hCG receptor on Leydig cells and tells them to produce testosterone. But it's not identical to LH — and the differences matter.

While you're on hCG, the testosterone it produces feeds back on the hypothalamus and pituitary through the standard negative feedback loop. The brain detects adequate testosterone and dials down its own GnRH and LH output. This isn't hCG damaging your pituitary — it's your thermostat working as designed.

A 2024 Fertility and Sterility study found that 71.4% of men on hCG (500-3,000 IU, three times weekly) had LH suppressed below 1 mIU/mL at 3 months. The pituitary goes quiet because it sees enough testosterone and says we're good.

But here's the critical difference from TRT: while the upstream signal is suppressed, the downstream hardware — your testes — stays fully online.

What hCG Preserves That TRT Destroys

This is the core argument for hCG monotherapy, and the data is striking.

Intratesticular Testosterone (ITT)

The Coviello et al. (2005) study in the Journal of Clinical Endocrinology & Metabolism is the landmark reference here. In 29 men receiving exogenous testosterone:

TRT alone crushed intratesticular testosterone by 94% — from 1,174 nmol/L down to 72 nmol/L. Adding just 250 IU of hCG every other day kept ITT within 7% of baseline. At 500 IU, ITT was 26% above baseline.

This matters because ITT is 50-100x higher than serum testosterone, and it's what drives spermatogenesis. When ITT collapses, sperm production stops. This is why TRT causes infertility and hCG doesn't.

Testicular Volume

Agarwal et al. (2020) compared hCG and testosterone in hypogonadotropic hypogonadism patients over ~13 months. The hCG group went from 2.5 mL to 8.3 mL testicular volume. The testosterone group barely changed — 3.24 to 3.4 mL.

In 17 men with isolated hypogonadotropic hypogonadism, Vicari et al. (1992) documented testicular volume increasing from 3.8 mL to 14.9 mL on hCG monotherapy over a mean of 22 months. Seventy percent achieved spermatogenesis without adding FSH.

Spermatogenesis

hCG monotherapy induces sperm production in 70% of men with hypogonadotropic hypogonadism. Adding FSH bumps it to 86%, but most men don't need it. Compare this to TRT, where up to 10% of men remain permanently azoospermic after discontinuation.

So What Happens When You Stop hCG?

This is where the literature gets thin — and where we need to be honest about what we know vs. what we're extrapolating.

The Good News: Pituitary Recovers Fast

The 2024 Fertility and Sterility study provides the most direct evidence. Among men who stopped hCG after 6 months of use (even with documented pituitary suppression — LH below 1 mIU/mL), pituitary hormones normalized within one month of discontinuation.

The FSH trajectory during and after hCG tells the story:

• During hCG (3 months): FSH 0.47 IU/L (suppressed)
• During hCG (6 months): FSH 1.59 IU/L (beginning to recover)
• During hCG (12 months): FSH 2.6 IU/L (still rising)
• After stopping hCG: normalized within the next monthly lab draw

This makes physiological sense. The pituitary wasn't damaged — it was responding appropriately to adequate testosterone levels. Remove the source of that testosterone (hCG), levels drop, and the pituitary re-engages within weeks.

The Testes Are Ready

Unlike post-TRT recovery, where the Leydig cells have been sitting idle and may have atrophied, post-hCG testes are primed. They've been actively producing testosterone the entire time. Testicular volume is maintained or increased. The machinery is warm.

When endogenous LH returns, the Leydig cells are ready to respond immediately. There's no atrophy to reverse, no months-long process of re-expanding testicular tissue.

The Uncomfortable Truth

Here's where I have to be direct about something the research makes clear but that many sources gloss over.

If your secondary hypogonadism was caused by something that hasn't changed, your axis will "restart" — back to its broken baseline.

The pituitary will resume signaling. The testes will respond. But if the reason your hypothalamus wasn't producing adequate GnRH in the first place is still present — obesity, chronic opioid use, a pituitary microadenoma, chronic stress, idiopathic dysfunction — then your "restarted" axis will produce the same inadequate testosterone it was producing before you started hCG.

hCG bypasses the problem. It doesn't fix it.

This is supported by data from the SERM literature. A study in Clinical Endocrinology tracked men with secondary hypogonadism who achieved normal testosterone on clomiphene citrate (mean 22.7 nmol/L during treatment). After stopping:

• 3 months later: testosterone dropped to 10.2 nmol/L
• 78% fell below the 11 nmol/L threshold
• By 6 months: all patients had returned to pre-treatment levels

The authors concluded: "Late-onset hypogonadism does not seem to be a reversible condition in most patients after clomiphene citrate treatment."

If SERMs — which work directly at the hypothalamic-pituitary level — can't produce lasting axis recovery in organic secondary hypogonadism, hCG (which works downstream of the problem) is even less likely to.

When Restart IS Possible

There are specific scenarios where the axis genuinely can recover after hCG monotherapy:

1. The Underlying Cause Was Addressed

If you were hypogonadal because of obesity and lost significant weight during treatment, the metabolic suppression of GnRH may have resolved. If you were on opioids and tapered off, the opioid-mediated GnRH suppression is gone. If hyperprolactinemia was treated with a dopamine agonist, GnRH inhibition from prolactin is removed.

In these cases, you may come off hCG to a better axis than the one you started with — because the upstream problem was fixed while hCG kept your testes functional.

2. AAS/TRT-Induced Suppression

If your secondary hypogonadism was iatrogenic — caused by prior testosterone or anabolic steroid use — the underlying axis is fundamentally intact. It just needs time to recover from exogenous suppression.

The data here is strong. Wenker et al. (2015) treated 49 men with TRT-induced azoospermia using hCG 3,000 IU every other day plus SERMs. 95.9% recovered spermatogenesis in an average of 4.6 months with a mean sperm density of 22.6 million/mL.

Kohn et al. (2017) showed that age and duration of prior testosterone use are the key predictors: each additional year of age reduces success probability by 1.71%, and each additional year of prior testosterone use reduces it by 3.06%.

3. Transient Causes

Acute illness, severe stress, overtraining, certain medications (antipsychotics, glucocorticoids) — these can cause temporary HPG axis suppression. Once the cause resolves, the axis often recovers on its own, and hCG would have kept the testes functional during the interim.

The Leydig Cell Question: Does Long-Term hCG Damage the Testes?

A common concern is that chronic hCG use might "burn out" the Leydig cells through desensitization. The research here is nuanced and dose-dependent.

Desensitization Is Real — At High Doses

Leydig cell desensitization from hCG involves multiple mechanisms:

1. Receptor downregulation — hCG binding triggers receptor internalization. In rats, a single 100 IU injection dropped receptor levels to 5-10% of normal within 3 days.
2. Signaling uncoupling — Adenylate cyclase responsiveness drops 40% within 2 hours, before receptors are even lost (Smals et al., 1984).
3. Cholesterol depletion — Esterified cholesterol (the raw material for steroidogenesis) drops 81% in desensitized cells.
4. Steroidogenic enzyme block — The 17,20-desmolase enzyme that converts precursors to androgens gets impaired.
5. At extreme doses: cell stress and apoptosis — Park et al. (2013) showed high-dose hCG induces endoplasmic reticulum stress and caspase-mediated apoptosis in Leydig cells, reducing cell viability to 66% at 24 hours.

But Not At Therapeutic Doses

The critical study is Smals et al. (1984), which compared a single 1,500 IU hCG bolus versus 300 IU daily for 5 days in 7 healthy men:

The single bolus caused a testosterone spike followed by a crash below baseline by day 7, with estradiol spiking 4.4x at 24 hours. The divided doses produced nearly double the total testosterone response (measured by area under the curve), no estradiol spike, and no desensitization.

For long-term use, Balducci et al. (1987) gave 6 hypogonadotropic men 1,500 IU hCG every 6 days for a full year. Not only was there no desensitization — testosterone responses progressively increased:

• Baseline: 11.2 ng/dL
• 4 months: basal 38.7 ng/dL, peak 198.3 ng/dL post-injection
• 12 months: basal 99.5 ng/dL, peak 415.6 ng/dL post-injection

The testes were becoming more responsive over time, not less. This is consistent with Leydig cell maturation under gonadotropin stimulation.

The takeaway: At therapeutic doses (1,000-2,000 IU, 2-3 times per week), Leydig cell desensitization does not appear to be a clinical problem over at least 1-2 years. The concern applies primarily to very high single-bolus dosing.

The Recovery Timeline: hCG vs. TRT

Bridging Off hCG: The SERM Transition

If you do want to attempt an axis restart after hCG monotherapy, the pharmacological logic for using a SERM (selective estrogen receptor modulator) as a bridge is sound:

1. Stop hCG. It clears in 3-5 days. Testosterone begins to drop.
2. Start a SERM (clomiphene 25 mg/day or enclomiphene 12.5-25 mg/day). The SERM blocks estrogen's negative feedback at the hypothalamus and pituitary, forcing LH and FSH upward.
3. Endogenous LH rises and takes over the job hCG was doing — telling the Leydig cells to produce testosterone.
4. Taper the SERM over 4-6 weeks and assess whether the axis sustains itself.

The most widely referenced clinical protocol comes from Defy Medical:

• hCG 300-400 IU daily for 14 days (testicular priming)
• Then stop hCG, start clomiphene 25 mg/day for 28 days (or enclomiphene 25 mg/day for 6 weeks)
• Wait 30 days after finishing, check labs: total/free T, sensitive estradiol, LH, FSH, CBC
• Success criterion: total testosterone above 500 ng/dL

Dr. Michael Scally published a more aggressive protocol (hCG 2,000 IU every other day for 20 days, overlapping with tamoxifen and clomiphene for 30-45 days) that achieved 100% axis recovery in 19 men after testosterone/nandrolone cycles.

Why SERMs Work as a Bridge

Enclomiphene data supports this mechanism. Wiehle et al. (BJU International) showed a "legacy effect" — after stopping enclomiphene, testosterone and LH remained elevated for at least a week beyond what drug half-life would explain. The hypothesis is that enclomiphene restores normal pulsatile LH secretion patterns, and that pattern persists briefly after the drug clears.

But — and this is important — forum data from patients combining hCG and enclomiphene simultaneously shows the combination counteracts the SERM's effect. One patient on enclomiphene 12.5 mg/day had LH of 20.8 mIU/mL. After adding hCG 300 IU four times weekly, LH dropped to 2.7 mIU/mL. The testosterone from hCG-stimulated production was feeding back and negating the SERM's pituitary stimulation. These drugs should be sequenced, not stacked.

The Honest Framework

Here's how I'd frame the decision based on everything the literature shows:

What the Literature Still Doesn't Know

I want to be transparent about the gaps, because they're significant:

1. No study has directly measured serial LH, FSH, and testosterone after stopping hCG monotherapy in men with non-iatrogenic secondary hypogonadism. This is the most glaring hole in the literature. Most discontinuation data comes from men recovering from TRT/AAS-induced suppression — a fundamentally different population.
2. No RCT compares axis recovery after hCG monotherapy vs. TRT. We're extrapolating from mechanism and indirect evidence.
3. Long-term Leydig cell effects beyond 1-2 years of hCG monotherapy are poorly characterized. The Balducci study ran 12 months. Anecdotal reports extend to 7 years. But rigorous multi-year data doesn't exist.
4. No study tests whether adding a SERM at the point of hCG discontinuation accelerates recovery compared to stopping hCG alone. The protocol is pharmacologically rational but not validated by controlled data.
5. The optimal taper strategy is unknown. Should you stop hCG cold? Taper the dose over weeks? Switch to lower frequency? Nobody has studied this systematically.

My Synthesis

If you're on hCG monotherapy for secondary hypogonadism and wondering whether you can come off, here's the evidence-based framework:

Your testes are in the best possible position. Unlike TRT, hCG maintained their size, their Leydig cell function, their intratesticular testosterone, and their spermatogenic capacity. When you stop hCG, the hardware is ready.

Your pituitary will re-engage quickly. Gonadotropin suppression from hCG appears to normalize within about a month of discontinuation. This is functional suppression, not structural damage.

Whether your axis produces adequate testosterone depends entirely on why it wasn't working in the first place. If the cause is gone, you have a real shot. If it's still present, you'll return to your hypogonadal baseline — which is not a failure of hCG or of your body, it's the nature of the disease.

A SERM bridge is pharmacologically rational but unproven in controlled settings for this specific transition. If you attempt it, sequence it — stop hCG first, then start the SERM. Don't overlap them.

If restart fails, that's diagnostic information. It confirms your secondary hypogonadism requires ongoing treatment — and hCG monotherapy remains one of the best options for long-term management, with preserved fertility, maintained testicular function, and a favorable safety profile.

The research on this question is frustratingly incomplete. But the mechanistic picture is clear: hCG monotherapy keeps every door open. That's its fundamental advantage, whether you're planning to walk through one of those doors someday or not.